Get the Stockscreener App
1.27
7.63%
0.09
Ironwood Pharmaceuticals Inc stock is traded at $1.27, with a volume of 2.92M.
It is up +7.63% in the last 24 hours and up +62.82% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$1.18
Open:
$1.21
24h Volume:
2.92M
Relative Volume:
1.40
Market Cap:
$206.29M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
31.75
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
+23.30%
1M Performance:
+62.82%
6M Performance:
-30.03%
1Y Performance:
-72.92%
1-Day Range:
$1.19
$1.3695
1-Week Range:
$1.04
$1.3695
52-Week Range:
$0.5271
$5.205
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.27 | 183.55M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates - MSN
Sectors Driving Future Growth for Ironwood Pharmaceuticals Inc. StockTrade Volume Report & Real-Time Sentiment Analysis - Newser
Historical volatility pattern of Ironwood Pharmaceuticals Inc. visualizedJuly 2025 Opening Moves & Short-Term High Return Ideas - Newser
Measuring Ironwood Pharmaceuticals Inc.’s beta against major indicesMarket Rally & Entry Point Confirmation Alerts - Newser
Ironwood Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Stock Recap & Daily Oversold Bounce Ideas - Newser
Keep An Eye On Ironwood Pharmaceuticals As Insider Stock Selling Hits US$515k - simplywall.st
Will Ironwood Pharmaceuticals Inc. benefit from rate cuts2025 Top Gainers & Stepwise Entry and Exit Trade Signals - classian.co.kr
Volume spikes in Ironwood Pharmaceuticals Inc. stock – what they meanWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
How to build a custom watchlist for Ironwood Pharmaceuticals Inc.Trade Risk Summary & Safe Entry Zone Identification - Newser
Risk adjusted return profile for Ironwood Pharmaceuticals Inc. analyzed2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Using fundamentals and technicals on Ironwood Pharmaceuticals Inc.Portfolio Return Summary & Weekly High Return Stock Opportunities - Newser
What to do if you’re stuck in Ironwood Pharmaceuticals Inc.Analyst Downgrade & Entry and Exit Point Strategies - Newser
Multi factor analysis applied to Ironwood Pharmaceuticals Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Published on: 2025-08-15 04:45:17 - Newser
Can Ironwood Pharmaceuticals Inc. be recession proofJuly 2025 Catalysts & Safe Entry Momentum Tips - classian.co.kr
Ironwood Pharmaceuticals Inc. Uptrend in Early Stages Indicators Say YesJuly 2025 Summary & AI Enhanced Trading Signals - newsyoung.net
Published on: 2025-08-14 14:41:22 - beatles.ru
Can Ironwood Pharmaceuticals Inc. expand its profit margins2025 Performance Recap & Verified Entry Point Detection - 선데이타임즈
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD) - The Globe and Mail
Short Bowel Syndrome Market to Experience Notable Growth - openPR.com
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
How high can Ironwood Pharmaceuticals Inc. stock goSmart Entry Signals for Active Traders - Newser
Ironwood Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ironwood: Q2 Earnings Snapshot - Connecticut Post
Ironwood Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ironwood (IRWD) Q2 EPS Jumps 600% - AOL.com
Ironwood Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Pharmaceuticals (IRWD.O) Surges 15.5% on Strong KDJ Signal Amid Mixed Peer Performance - AInvest
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - BioSpace
Ironwood Pharmaceuticals Q2 2025 Earnings: EPS of $0.15 and Reve - GuruFocus
Ironwood Pharmaceuticals Tops Expectations With Strong Q2 Results - Finimize
Ironwood Pharmaceuticals (IRWD) Projected to Post Quarterly Earnings on Thursday - Defense World
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Ironwood Pharmaceuticals Inc expected to post earnings of 4 cents a shareEarnings Preview - TradingView
Custom Dashboard Highlights Ironwood Pharmaceuticals Inc. Price MomentumFundamental Growth Stock Analysis Shows Strength - beatles.ru
Published on: 2025-08-04 00:15:09 - Jammu Links News
What drives Ironwood Pharmaceuticals Inc. stock priceExpert guidance for superior capital growth - Jammu Links News
Is Ironwood Pharmaceuticals Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is it the right time to buy Ironwood Pharmaceuticals Inc. stockOutstanding risk-reward balance - Jammu Links News
Is Ironwood Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with strong growth potential - Jammu Links News
What are the technical indicators suggesting about Ironwood Pharmaceuticals Inc.Build a winning investment strategy - Jammu Links News
What are the latest earnings results for Ironwood Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What catalysts could drive Ironwood Pharmaceuticals Inc. stock higher in 2025Achieve breakthrough financial growth - Jammu Links News
How strong is Ironwood Pharmaceuticals Inc. company’s balance sheetDynamic portfolio growth - Jammu Links News
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyExceptional financial outcomes - Jammu Links News
What Fibonacci levels say about Ironwood Pharmaceuticals Inc. reboundAutomated AI Forecast with Trading Alerts - Newser
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Aug 11 '25 |
Sale |
0.84 |
7,754 |
6,513 |
400,378 |
| Martini Gregory S. | Chief Financial Officer |
Aug 11 '25 |
Sale |
0.84 |
1,265 |
1,063 |
182,545 |
| Silver Ronald | Principal Accounting Officer |
Aug 11 '25 |
Sale |
0.84 |
2,846 |
2,391 |
276,809 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):